Xenon Pharmaceuticals Inc represents values of innovation, collaboration, and commitment to improving patients' lives. As a leading biopharmaceutical company, Xenon strives to develop innovative therapies for serious medical conditions. Their corporate philosophy emphasizes the importance of scientific excellence, integrity, and patient-centered focus. They leverage their expertise in human genetics and biology to discover and develop novel drugs. With a strong dedication to scientific research and a goal to address unmet medical needs, Xenon Pharmaceuticals Inc remains focused on advancing the forward-thinking ideas that drive their drug development pipeline.

Xenon Pharmaceuticals Inc is primarily present in North America, with its headquarters located in Burnaby, British Columbia, Canada. The company's strong presence in this region allows it to leverage the local healthcare infrastructure and expertise. Additionally, Xenon Pharmaceuticals Inc has expanded its operations in the United States, establishing partnerships with various biopharmaceutical companies. Through these collaborations, Xenon Pharmaceuticals Inc aims to advance the development of innovative therapeutic solutions. By focusing on its strategic presence in North America, Xenon Pharmaceuticals Inc is well-positioned to drive growth and address critical unmet medical needs in the region.

Xenon Pharmaceuticals Inc has achieved several significant milestones. The company successfully advanced its lead product candidate, XEN496, for the treatment of epilepsy, into Phase 2 clinical trials. Xenon has also collaborated with major pharmaceutical companies, including Genentech and Teva, to develop novel therapies for neurological disorders. Additionally, the company has expanded its pipeline by identifying several promising drug candidates. Xenon's dedication to innovation and its focus on developing treatments for rare disorders have contributed to its success in advancing the field of precision medicine.

Xenon Pharmaceuticals Inc is a biopharmaceutical company that focuses on discovering and developing innovative therapeutics for rare diseases. Established in 1996, Xenon has a rich history in genetic research and has successfully advanced numerous programs into clinical trials. With its proprietary Extreme Genetics® platform, the company identifies and validates targets that are not accessible through conventional methods. Xenon has established strategic collaborations with leading pharmaceutical companies as well as received significant support from research grants and partnerships. By leveraging its expertise and cutting-edge technologies, Xenon Pharmaceuticals Inc is committed to delivering breakthrough therapies to patients in need.

The main competitors of Xenon Pharmaceuticals Inc in the market include other pharmaceutical companies such as Novartis AG, Pfizer Inc, and Johnson & Johnson. These companies also operate in the biotechnology sector and develop innovative drug therapies. However, Xenon Pharmaceuticals Inc distinguishes itself through its focus on discovering and developing small molecule therapeutics. With its unique approach and strong pipeline, Xenon Pharmaceuticals Inc competes effectively in the market against these competitors.

Xenon Pharmaceuticals Inc primarily operates in the pharmaceutical and biotechnology industries. With a focus on discovering and developing innovative therapeutics, Xenon is dedicated to improving the lives of patients by advancing precision medicine. The company's research and development efforts are aimed at creating novel treatments for neurological and cardiovascular disorders. Xenon's expertise lies in the identification of rare genetic mutations and their correlation with specific diseases, leading to the development of targeted therapies. Leveraging their deep understanding of human genetics, Xenon Pharmaceuticals Inc is pioneering advancements in precision medicine to address unmet medical needs.

The business model of Xenon Pharmaceuticals Inc. revolves around drug discovery and development. As a biopharmaceutical company, Xenon focuses on identifying and developing innovative therapeutics for various medical conditions. By leveraging their extensive expertise in genetics and genomics, Xenon aims to create novel treatments that target specific diseases and improve patient outcomes. With a strong emphasis on research and collaboration, Xenon's business model involves identifying promising drug candidates, conducting preclinical and clinical studies, and ultimately seeking regulatory approval for commercialization. Through their dedication to scientific innovation and strategic partnerships, Xenon Pharmaceuticals Inc. strives to bring transformative therapies to patients in need.

Az KGV a Xenon Pharmaceuticals esetében jelenleg nem számítható ki.

A Xenon Pharmaceuticals számára az aktuális KUV nem számítható ki.

Az AlleAktien Minőségi Score Xenon Pharmaceuticals esetében 2/10.

A várt Xenon Pharmaceuticals forgalma 5,42 Mió. USD.

A(z) várt Xenon Pharmaceuticals nyereség -279,82 Mió. USD.

Xenon Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery and development of innovative therapeutics. Our research and development is focused on the areas of pain, neurological diseases, and rare diseases. Our business model is based on identifying promising groundbreaking technologies and therapeutics, which we evaluate through extensive clinical studies and stringent regulation before bringing them to market. We have a broad portfolio of products and therapeutics in various stages of development. Our flagship product, XEN496, is a selective modulator for the neuronal potassium channel KCNQ2/3, developed for the treatment of epilepsy and other neurological disorders. The product has been proven safe and effective in Phase II trials, and we are now preparing for Phase III trials. In addition to XEN496, we have other products in the development phase, such as XEN1101, a modified GABAA receptor modulator developed for the treatment of epilepsy and anxiety disorders, and XEN901, a selective modulator for the potassium channel Nav1.6, developed for the treatment of pain. We also work closely with our partners to develop innovative therapeutic solutions. An example is our joint program with Genentech, where we are working on the identification of G-quadruplex-based therapeutics for rare diseases. We generate revenue through licensing and selling our products to other companies, research collaborations with our partners, and the sale of licenses for our own patents. Research and development are at the heart of our business model. We constantly invest in our research areas and technologies to make groundbreaking discoveries and develop innovative therapeutics that can improve the lives of patients worldwide. Overall, Xenon Pharmaceuticals Inc is an exciting biopharmaceutical company focused on the discovery and development of innovative therapeutics for pain, neurological diseases, and rare diseases. We are proud to be leaders in this field, and our business model will help ensure our future growth.

A(z) Xenon Pharmaceuticals évente alkalommal oszt ki 0 USD összegű osztalékot.

A Xenon Pharmaceuticals esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Xenon Pharmaceuticals ISIN kódja: CA98420N1050.

A Xenon Pharmaceuticals WKN-je A12ETN.

Az Xenon Pharmaceuticals tőzsdei rövidítése XENE.

Az elmúlt 12 hónapban a(z) Xenon Pharmaceuticals osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Xenon Pharmaceuticals várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) Xenon Pharmaceuticals jelenlegi osztalékhozama .

A(z) Xenon Pharmaceuticals negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Xenon Pharmaceuticals az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Xenon Pharmaceuticals a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Xenon Pharmaceuticals által 2025. 01. 16.-án/én fizetett 0 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2025. 01. 16.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2025. 01. 16. időpontban történt.

2024 évben a Xenon Pharmaceuticals 0 USD összegű osztalékot fizetett ki.

Az Xenon Pharmaceuticals osztalékait USD fizeti ki.